| Myriad misses Street 1Q forecasts | |
| | |
|
SALT LAKE CITY (AP) _ Myriad Genetics Inc. (MYGN) on Tuesday reported earnings of $16 million in its fiscal first quarter.
On a per-share basis, the Salt Lake City-based company said it had profit of 21 cents. Earnings, adjusted for costs related to mergers and acquisitions, came to 25 cents per share.
The results did not meet Wall Street expectations. The average estimate of analysts surveyed by Zacks Investment Research was for earnings of 31 cents per share.
The molecular diagnostic company posted revenue of $168.8 million in the period, which also fell short of Street forecasts. Analysts expected $174.2 million, according to Zacks.
For the current quarter ending in December, Myriad expects its per-share earnings to range from 33 cents to 36 cents.
The company said it expects revenue in the range of $180 million to $185 million for the fiscal second quarter.
Myriad expects full-year earnings in the range of $1.90 to $2 per share, with revenue ranging from $800 million to $820 million.
Myriad shares have risen 76 percent since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $36.89, an increase of 45 percent in the last 12 months.
_____
This story was generated by Automated Insights using data from Zacks Investment Research. MYGN stock research report from Zacks.
_____
Keywords:Myriad Genetics,Earnings Report
|
|
| |
ProfilIndicateurs de MarchéVALEUR : Projets & res.Communiqués de PresseRapport annuelRISQUE : Profile actifsContactez la cie |
Myriad Genetics est une société basée aux Etats-Unis D'Amerique. Myriad Genetics est cotée aux Etats-Unis D'Amerique. Sa capitalisation boursière aujourd'hui est 1,7 milliards US$ (1,6 milliards €). La valeur de son action a atteint son plus bas niveau récent le 29 mai 1998 à 10,00 US$, et son plus haut niveau récent le 17 novembre 2000 à 94,06 US$. Myriad Genetics possède 68 090 000 actions en circulation. |